m.koreaherald.com
Cure8 news brief
Why This Matters
Many people with Crohn’s disease or ulcerative colitis use biologic drugs; new clinical and real-world data about a subcutaneous infliximab option could affect treatment choice, switching decisions, and practical use in long-term care.
Updates presented at a major gastroenterology conference may influence clinicians’ prescribing practices in Europe and elsewhere.
Who Should Pay Attention
Patients with IBD considering biologic treatment or switching formulation, clinicians who treat IBD, and researchers following biologic therapy and real-world evidence in IBD.
Study Snapshot
Story typeResearch news
Evidence typeConference abstract
Source depthFull source text
What To Know
Celltrion will present clinical and real-world data on its subcutaneous infliximab product Remsima SC at United European Gastroenterology (UEG) Week 2026, alongside presentations and sessions about switching and long-term use in Crohn’s disease and ulcerative colitis.
The company also plans to showcase its IV Remsima, liquid IV formulation, and two other IBD biologics, Yuflyma (adalimumab) and Steqeyma (ustekinumab), and will host expert-led sessions and a symposium on subcutaneous infliximab clinical experience.
Key session topics described in the article include Remsima SC monotherapy real-world evidence, clinical considerations when switching Crohn’s patients to the subcutaneous formulation, and broader clinical use from early treatment through long-term management. Presenting experts named include Peter M. Irving, Irina Blumenstein, and Gionata Fiorino.
This item is a news report about conference presentations and company promotion of its IBD portfolio rather than a peer-reviewed study report; no specific trial results or numerical outcomes are provided in the article.
Keep In Mind
This is a conference/industry news item describing planned presentations and company-provided data — the article does not report full study methods, results, or peer-reviewed findings. Interpret any clinical implications cautiously until the underlying abstracts or full study reports are available.
Source Details
Review the original publication for the complete reporting, methods, and context.
Conference abstract
Article type assigned from Cure8 classification; confirm details in the original source.
Publicationm.koreaherald.com
AuthorsLim Ye-jin
Indexed viaGoogle News
Source typeWeb article
PublishedOct 15, 2026, 3:08 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Impact of Smoking on the Effectiveness of Advanced Therapies in Inflammatory Bowel Disease: Active Smoking Is Associated with Reduced Effectiveness of Anti-TNF Treatment
The study suggests active smoking reduces the effectiveness of anti-TNF biologics in people with IBD, which could affect treatment response and the need to switch or escalate therapies. This supports including smoking...
Patterns and factors associated with dose escalation during maintenance treatment for inflammatory bowel disease: a population-based cohort study.
Dose increases are common during IBD maintenance and vary a lot by drug and patient profile. Knowing which treatments and patient factors are linked to escalation can help patients and clinicians plan monitoring and...
Beyond class switching in multi-refractory inflammatory bowel disease: Nine case reports and review of literature
For people with multi-refractory Crohn’s disease or ulcerative colitis, adding a JAK inhibitor to an existing biologic (advanced combination therapy) may convert partial responses into deeper remission in selected cases,...